Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Endocrinological Investigation
Published in: Journal of Endocrinological Investigation 9/2015

01-09-2015 | Consensus Statement

How to manage the reproductive issues of PCOS: a 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology

Authors: P. Moghetti, E. Carmina, V. De Leo, A. Lanzone, F. Orio, R. Pasquali, V. Toscano

Published in: Journal of Endocrinological Investigation | Issue 9/2015

Login to get access

Excerpt

Reproductive alterations are a mainstay of the classic definition of polycystic ovary syndrome (PCOS), as defined in 1992 by the NIH consensus statement on PCOS [1]. These abnormalities still represent one of the three cardinal aspects used for diagnosing PCOS according to the current criteria, as defined by the Rotterdam ESHRE/ASRM consensus workshop [2] and by the AE-PCOS Society [3]. In addition, the reproductive alterations of PCOS are a key point in the treatment of this condition. …
Literature
1.
Zawadski JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR (eds) Polycystic ovary syndrome. Blackwell Scientific Publications, Boston, pp 377–384
2.
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47CrossRef
3.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF, Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society (2009) The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91:456–488CrossRefPubMed
4.
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, GRADE Working Group et al (2004) Grading quality of evidence and strength of recommendations. Br Med J 328:1490–1494CrossRef
5.
Swiglo BA, Murad MH, Schunemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM (2008) A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 93:666–673CrossRefPubMed
6.
Apter D, Sibila I (1993) Development of children and adolescence: physiological, pathophysiological, and therapeutic aspects. Curr Opin Obstet Gynecol 5:764–773CrossRefPubMed
7.
Fanelli F, Gambineri A, Belluomo I, Repaci A, Di Lallo VD, Di Dalmazi G, Mezzullo M, Prontera O, Cuomo G, Zanotti L et al (2013) Androgen profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in healthy normal-weight ovulatory and anovulatory late adolescent and young women. J Clin Endocrinol Metab 98:3058–3067CrossRefPubMed
8.
Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS et al (2012) Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97:28–38CrossRefPubMed
9.
Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK (2013) Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 98:4565–4592CrossRefPubMed
10.
Bolùmar F, Olsen J, Rabagliato M, Sàez-Lloret I, Bisanti L (2000) Body mass index and delayed conception: a European multicenter study on infertility and subfecundity. Am J Epidemiol 151:1072–1079CrossRefPubMed
11.
Familiari G, Toscano V, Motta PM (1985) Morphological studies of polycystic mouse ovaries induced by dehydroepiandrosterone. Cell Tissue Res 240:519–528CrossRefPubMed
12.
Sen A, Prizant H, Light A, Biswas A, Hayes E, Lee HJ, Barad D, Gleicher N, Hammes SR (2014) Androgens regulate ovarian follicular development by increasing follicle stimulating hormone receptor and microRNA-125b expression. Proc Natl Acad Sci USA 111:3008–3013PubMedCentralCrossRefPubMed
13.
Blank SK, McCartney CR, Chhabra S, Helm KD, Eagleson CA, Chang RJ, Marshall JC (2009) Modulation of gonadotropin-releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls—implications for regulation of pubertal maturation. J Clin Endocrinol Metab 94:2360–2366PubMedCentralCrossRefPubMed
14.
Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, Griesinger G, Kelsey TW, La Marca A, Lambalk C (2014) The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 20:370–385CrossRefPubMed
15.
Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33:981–1030CrossRefPubMed
16.
Tosi F, Negri C, Perrone F, Dorizzi R, Castello R, Bonora E, Moghetti P (2012) Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome. J Clin Endocrinol Metab 97:1712–1719CrossRefPubMed
17.
Tosi F, Negri C, Brun E, Castello R, Faccini G, Bonora E, Muggeo M, Toscano V, Moghetti P (2011) Insulin enhances ACTH-stimulated androgen and glucocorticoid metabolism in hyperandrogenic women. Eur J Endocrinol 164:197–203CrossRefPubMed
18.
Pasquali R, Patton L, Pocognoli P, Cognigni GE, Gambineri A (2007) 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. J Clin Endocrinol Metab 92:4208–4217CrossRefPubMed
19.
Pastor CL, Griffin-Korf ML, Aloi JA, Evans WS, Marshall JC (1998) Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 83:582–590PubMed
20.
O’Connor A, Phelan N, Tun TK, Boran G, Gibney J, Roche HM (2010) High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. J Clin Endocrinol Metab 95:1378–1385CrossRefPubMed
21.
Maleszka A, Smolinska N, Nitkiewicz A, Kiezun M, Chojnowska K, Dobrzyn K, Szwaczek H, Kaminski T (2014) Adiponectin Expression in the Porcine Ovary during the Oestrous Cycle and Its Effect on Ovarian Steroidogenesis. Int J Endocrinol 2014:957076PubMedCentralCrossRefPubMed
22.
23.
Merhi Z (2014) Advanced glycation end products and their relevance in female reproduction. Hum Reprod 29:135–145CrossRefPubMed
24.
Tantalaki E, Piperi C, Livadas S, Kollias A, Adamopoulos C, Koulouri A, Christakou C, Diamanti-Kandarakis E (2014) Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones (Athens) 13:65–73
25.
Hsueh AJ, Kawamura K, Cheng Y, Fauser BC (2014) Intraovarian control of early folliculogenesis. Endocr Rev 9:er20141020 [Epub ahead of print]
26.
Pasquali R, Gambineri A, Cavazza C, Ibarra Gasparini D, Ciampaglia W, Cognigni GE, Pagotto U (2011) Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol 164:53–60CrossRefPubMed
27.
Domecq JP, Prutsky G, Mullan RJ, Hazem A, Sundaresh V, Elamin MB, Phung OJ, Wang A, Hoeger K, Pasquali R et al (2013) Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J Clin Endocrinol Metab 98:4655–4663CrossRefPubMed
28.
Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ (1998) Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 13:1502–1505CrossRefPubMed
29.
Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G (2003) Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 18:1928–1932CrossRefPubMed
30.
Farquhar C, Brown J, Marjoribanks J (2012) Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 6:CD001122PubMed
31.
Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2008) Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 89:505–522CrossRef
32.
ACOG Committee on Practice Bulletins—Gynecology (2009) ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. Obstet Gynecol 114:936–949CrossRef
33.
Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E (2009) Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 4:CD002249PubMed
34.
Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH (2012) Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligoamenorrhoea and subfertility. Cochrane Database Syst Rev 5:CD003053PubMed
35.
Homburg R, Hendriks ML, König TE, Anderson RA, Balen AH, Brincat M, Child T, Davies M, D’Hooghe T, Martinez A, Rajkhowa M, Rueda-Saenz R, Hompes P, Lambalk CB (2012) Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study. Hum Reprod 27:468–473CrossRefPubMed
36.
Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R, NICHD Reproductive Medicine Network et al (2014) Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 371:119–129PubMedCentralCrossRefPubMed
37.
Moll E, van der Veen F, van Wely M (2007) The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 13:527–537CrossRefPubMed
38.
Vause TD, Cheung AP, Sierra S, Claman P, Graham J, Guillemin JA, Lapensée L, Steward S, Wong BC (2010) Society of Obstetricians and Gynaecologists of Canada. Int J Gynaecol Obstet 111:95–100CrossRefPubMed
39.
Moll E, Korevaar JC, Bossuyt PM, van der Veen F (2008) Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome? Hum Reprod 23:1830–1834PubMedCentralCrossRefPubMed
40.
Li HW, Lee VC, Lau EY, Yeung WS, Ho PC, Ng EH (2014) Cumulative live-birth rate in women with polycystic ovary syndrome or isolated polycystic ovaries undergoing in vitro fertilisation treatment. J Assist Reprod Genet 31:205–211PubMedCentralCrossRefPubMed
41.
Palomba S, Falbo A, La Sala GB (2013) Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG 120:267–276CrossRefPubMed
42.
Heijnen EMEW, Eijkemans MJC, Hughes EG, Laven JSE, Macklon NS, Fauser BCJM (2006) A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update 12:13–21CrossRefPubMed
43.
Leader A; Monofollicular Ovulation Induction Study Group (2006) Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low-dose step-up protocol with weekly increments of 25 international units of follicle-stimulating hormone. Fertil Steril 85:1766–1773CrossRef
44.
van Wely M, Bayram N, van der Veen F (2003) Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome: a systematic review based on a Cochrane review. Hum Reprod 18:1143–1149CrossRefPubMed
45.
Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y (2012) Meta-analysis of GnRH antagonist Protocols: do they reduce the risk of OHSS in PCOS? Reprod Biomed Online 24:6–22CrossRefPubMed
46.
Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Macedo CR (2014) Metformin Treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 11:CD006105PubMed
47.
Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, Pugeat M, Qiao J, Wijeyaratne CN, Witchel SF, Norman RJ (2012) Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 18:146–170CrossRefPubMed
48.
Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S (1992) Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36:105–111CrossRef
49.
Kuchenbecker WK, Groen H, van Asselt SJ, Bolster JH, Zwerver J, Slart RH, Vd Jagt EJ, Muller Kobold AC, Wolffenbuttel BH, Land JA, Hoek A (2011) In women with polycystic ovary syndrome and obesity, loss of intra-abdominal fat is associated with resumption of ovulation. Hum Reprod 26:2505–2512CrossRefPubMed
50.
Palomba S, Falbo A, Zullo F, Orio F Jr (2009) Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 30:1–50CrossRefPubMed
51.
Carmina E (2013) Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome. J Endocrinol Invest 36:358–363PubMed
52.
Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E (2011) Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ 343:d6423PubMedCentralCrossRefPubMed
53.
Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N (2012) Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 366:2257–2266CrossRefPubMed
54.
Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, Lehnert H (2012) Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 33:812–841PubMedCentralCrossRefPubMed
55.
Vandenheuvel MW, VanBragt AJ, Alnabawy AK, Kaptein MC (2005) Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 72:168–174CrossRef
56.
Guastella E, Longo RA, Carmina E (2010) Clinical and endocrine characteristics of the main PCOS phenotypes. Fertil Steril 94:2197–2201CrossRefPubMed
57.
Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, Giagulli VA, Signori C, Zambotti F, Dall’Alda M, Spiazzi G, Zanolin ME, Bonora E (2013) Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab 98:E628–E637CrossRefPubMed
58.
Lopez LM, Grimes DA, Schulz KF (2014) Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 4:CD006133PubMed
59.
Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JA (2013) Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ 185:E115–E120PubMedCentralCrossRefPubMed
60.
61.
Lenzer J (2011) US panel rules that warnings on two birth control pills be strengthened. BMJ 343:d8104CrossRefPubMed
62.
Burke AE (2011) The state of hormonal contraception today: benefits and risks of hormonal contraceptives: progestin-only contraceptives. Am J Obstet Gynecol 205(4 Suppl):S14–S17CrossRefPubMed
63.
Lidegaard Ø (2014) Hormonal contraception, thrombosis and age. Expert Opin Drug Saf 13:1353–1360CrossRefPubMed
64.
De Leo V, la Marca A, Petraglia F (2003) Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24:633–667CrossRefPubMed
65.
66.
Moghetti P (2012) For what reasons should metformin be used in the management of polycystic ovary syndrome? J Endocrinol Invest 35:87–89PubMed
67.
Panidis D, Tziomalos K, Papadakis E, Kandaraki EA, Katsikis I (2013) The guidelines issued by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine regarding the induction of ovulation with metformin in patients with the polycystic ovary syndrome potentially require reconsideration. Hormones (Athens) 12:192–200CrossRef
68.
Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, Kelestimur F, Macut D, Micic D, Pasquali R, Pfeifer M, Pignatelli D, Pugeat M, Yildiz BO, ESE PCOS Special Interest Group (2014) The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 171:P1–P29CrossRefPubMed
69.
Christakou C, Kollias A, Piperi C, Katsikis I, Panidis D, Diamanti-Kandarakis E (2014) The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones (Athens) 13:488–497
70.
Glintborg D, Altinok ML, Mumm H, Hermann AP, Ravn P, Andersen M (2014) Body composition is improved during 12 months’ treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab 99:2584–2591CrossRefPubMed
71.
Johansson J, Stener-Victorin E (2013) Polycystic ovary syndrome: effect and mechanisms of acupuncture for ovulation induction. Evid Based Complement Alternat Med 2013:762615PubMedCentralCrossRefPubMed
72.
Raval AD, Hunter T, Stuckey B, Hart RJ (2011) Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev 10:CD008565PubMed
73.
Puurunen J, Piltonen T, Puukka K, Ruokonen A, Savolainen MJ, Bloigu R, Morin-Papunen L, Tapanainen JS (2013) Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 98:4798–4807CrossRefPubMed
74.
Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C, Pagotto U, Pasquali R (2006) Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 91:3970–3980CrossRefPubMed
75.
Brahm J, Brahm M, Segovia R, Latorre R, Zapata R, Poniachik J, Buckel E, Contreras L (2011) Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature. Ann Hepatol 10:93–98PubMed
76.
Bruni V, Peruzzi E, Dei M, Nannini S, Seravalli V, Sisti G, Fambrini M (2012) Hepatotoxicity with low- and ultralow-dose flutamide: a surveillance study on 203 hyperandrogenic young females. Fertil Steril 98:1047–1052CrossRefPubMed
77.
Escobar-Morreale HF (2012) Surgical management of metabolic dysfunction in PCOS. Steroids 77:312–316CrossRefPubMed
78.
Falsetti L, Pasinetti E (1995) Effects of long term administration of an oral contraceptive containing ethinyl/estradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 74:56–60CrossRefPubMed
79.
Escobar-Morreale H, Asuncion MA, Sancho J (2000) Treatment of hirsutism with ethinyl/estradiol desogestrel contraceptive pills has beneficial effects on lipid profile and improves insulin sensitivity. Fertil Steril 74:816–819CrossRefPubMed
80.
Cibula D, Fanta M, Hill M, Sindelka A, Skrha J, Zivny J (2002) Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low androgenic progestin. Hum Reprod 17:76–82CrossRefPubMed
81.
Elter K, Imir G, Durmusoglu F (2002) Clinical, endocrine and metabolic effects of metformin added to ethinyl/estradiol-cyproterone acetate in non-obese women with polycystic ovary syndrome: a randomized control study. Hum Reprod 17:1729–1737CrossRefPubMed
82.
Cagnacci A, Paoletti AM, Renzi A, Orrù M, Pilloni M, Melis GB, Volpe A (2003) Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab 88:3621–3625CrossRefPubMed
83.
Morin Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS (2003) Metformin versus ethinyl/estradiol-cyproterone acetate in the treatment of non-obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:148–156CrossRefPubMed
84.
Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR (2010) Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril 94:1793–1798CrossRefPubMed
85.
Uras R, Orrù M, Pani F, Marotto MF, Pilloni M, Guerriero S, Etzi R, Zedda P, Sorge R, Lello S, Melis GB, Paoletti AM (2010) Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome. Contraception 82:131–138CrossRefPubMed
86.
Cullberg G, Hamberger L, Mattsson LA, Mobacken H, Samsioe G (1985) Effect of low dose desogestrel-ethinyl/estradiol combination on hirsutism, androgens and sex hormone binding globulins in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 64:195–202CrossRefPubMed
87.
Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, Lanzone A (2004) Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 89:2817–2823CrossRefPubMed
88.
Vribokova J, Cibula D (2005) Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 11:277–291CrossRef
89.
Rautio K, Tapanainen JC, Ruokonen A, Morin-Papunen LC (2005) Effects of metformin and ethinyl/estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 152:269–275CrossRefPubMed
90.
Nader S, Riad Gabriel MG, Saad MF (1997) The effect of desogestrel containing oral contraceptives on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab 82:3074–3077PubMed
91.
Morin-Papunen LC, Vauhkonen K, Koivunen RM, Puokonen A, Martikainen HK, Tapanainen JS (2000) Endocrine and metabolic effects of metformin versus ethinyl/estradiol cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 85:3161–3168PubMed
92.
Palep Singh M, Barth JH, Mook K, Balen AH (2004) An observation study of Yasmin in the management of polycystic ovary syndrome. J Fam Plan Repro Health Care 30:163–165CrossRef
93.
Cibula D, Hill M, Fanta M, Sindelka G, Zivny J (2001) Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovary syndrome? Hum Reprod 16:940–944CrossRefPubMed
94.
Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ (2007) Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 92:456–461CrossRefPubMed
Metadata
Title
How to manage the reproductive issues of PCOS: a 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology
Authors
P. Moghetti
E. Carmina
V. De Leo
A. Lanzone
F. Orio
R. Pasquali
V. Toscano
Publication date
01-09-2015
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 9/2015
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-015-0274-y

Other articles of this Issue 9/2015

Journal of Endocrinological Investigation 9/2015 Go to the issue

Original Article

The prevalence of benign breast diseases in patients with nodular goiter and Hashimoto’s thyroiditis

Original Article

Does segmental body composition differ in women with Prader–Willi syndrome compared to women with essential obesity?

Short Review

Bone health in type 1 diabetes: focus on evaluation and treatment in clinical practice

Original Article

Reference ranges for an automated chemiluminescent assay for serum insulin-like growth factor I (IGF-I) in a large population of healthy adults from Buenos Aires

Review

Myocardial fat as a part of cardiac visceral adipose tissue: physiological and pathophysiological view

Original Article

SIAMS survey on sexological screening during the assisted reproductive technologies in Italy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits